143 related articles for article (PubMed ID: 37145970)
21. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling.
Yuan M; Meng XW; Ma J; Liu H; Song SY; Chen QC; Liu HY; Zhang J; Song N; Ji FH; Peng K
Drug Des Devel Ther; 2019; 13():3137-3149. PubMed ID: 31564830
[TBL] [Abstract][Full Text] [Related]
22. Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3β in Rats.
Qiao S; Mao X; Wang Y; Lei S; Liu Y; Wang T; Wong GT; Cheung CW; Xia Z; Irwin MG
Crit Care Med; 2016 Mar; 44(3):e131-45. PubMed ID: 26468894
[TBL] [Abstract][Full Text] [Related]
23. Dexmedetomidine preconditioning may attenuate myocardial ischemia/reperfusion injury by down-regulating the HMGB1-TLR4-MyD88-NF-кB signaling pathway.
Zhang JJ; Peng K; Zhang J; Meng XW; Ji FH
PLoS One; 2017; 12(2):e0172006. PubMed ID: 28222157
[TBL] [Abstract][Full Text] [Related]
24. Dexmedetomidine attenuates renal ischemia-reperfusion injury through activating PI3K/Akt-eNOS signaling via α
Shan X; Zhang J; Wei X; Tao W; Peng K; Liu H; Wang Y; Liu H; Meng X; Ji F
FASEB J; 2022 Nov; 36(11):e22608. PubMed ID: 36250975
[TBL] [Abstract][Full Text] [Related]
25. Effects of Dexmedetomidine Postconditioning on Myocardial Ischemia/Reperfusion Injury in Diabetic Rats: Role of the PI3K/Akt-Dependent Signaling Pathway.
Cheng X; Hu J; Wang Y; Ye H; Li X; Gao Q; Li Z
J Diabetes Res; 2018; 2018():3071959. PubMed ID: 30402501
[TBL] [Abstract][Full Text] [Related]
26. Effect of dexmedetomidine and cholinergic anti-inflammatory pathways in myocardial ischemia-reperfusion injury.
Ju Y; Xiao F; Lu J; Zhou B; Cai J; Chen S
Pak J Pharm Sci; 2020 May; 33(3(Special)):1377-1382. PubMed ID: 33361026
[TBL] [Abstract][Full Text] [Related]
27. Ozone protects cardiomyocytes against ischemia/reperfusion injury: Regulating the heat shock protein 70 (HPS70) expression through activating the JAK2/STAT3 Pathway.
Yu S; Guo H; Luo Y; Chen H
Bioengineered; 2021 Dec; 12(1):6606-6616. PubMed ID: 34516361
[TBL] [Abstract][Full Text] [Related]
28. Dexmedetomidine Attenuates Ischemia/Reperfusion-Induced Myocardial Inflammation and Apoptosis Through Inhibiting Endoplasmic Reticulum Stress Signaling.
Yang YF; Wang H; Song N; Jiang YH; Zhang J; Meng XW; Feng XM; Liu H; Peng K; Ji FH
J Inflamm Res; 2021; 14():1217-1233. PubMed ID: 33833544
[TBL] [Abstract][Full Text] [Related]
29. Matrine Protects Cardiomyocytes From Ischemia/Reperfusion Injury by Regulating HSP70 Expression Via Activation of the JAK2/STAT3 Pathway.
Guo S; Gao C; Xiao W; Zhang J; Qu Y; Li J; Ye F
Shock; 2018 Dec; 50(6):664-670. PubMed ID: 29394239
[TBL] [Abstract][Full Text] [Related]
30. Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat.
Tang C; Hu Y; Gao J; Jiang J; Shi S; Wang J; Geng Q; Liang X; Chai X
Life Sci; 2020 Sep; 257():118004. PubMed ID: 32621918
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of dexmedetomidine against diabetic hyperglycemia-exacerbated cerebral ischemia/reperfusion injury: An in vivo and in vitro study.
Chen L; Cao J; Cao D; Wang M; Xiang H; Yang Y; Ying T; Cong H
Life Sci; 2019 Oct; 235():116553. PubMed ID: 31185237
[TBL] [Abstract][Full Text] [Related]
32. Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis.
Wang L; Liu J; Wang Z; Qian X; Zhao Y; Wang Q; Dai N; Xie Y; Zeng W; Yang W; Bai X; Yang Y; Qian J
Biomed Pharmacother; 2023 Sep; 165():115255. PubMed ID: 37549462
[TBL] [Abstract][Full Text] [Related]
33. Dexmedetomidine pretreatment alleviates cerebral ischemia/reperfusion injury by inhibiting neuroinflammation through the JAK2/STAT3 pathway.
Liu H; Li J; Jiang L; He J; Zhang H; Wang K
Braz J Med Biol Res; 2022; 55():e12145. PubMed ID: 35858000
[TBL] [Abstract][Full Text] [Related]
34. Dexmedetomidine alleviates myocardial ischemia/reperfusion-induced injury and Ca
Zheng X; Li J; Fan Q; Zhao X; Chen K
Int J Cardiol; 2021 Sep; 338():185-195. PubMed ID: 33731281
[TBL] [Abstract][Full Text] [Related]
35. Role of Keap1-Nrf2/ARE signal transduction pathway in protection of dexmedetomidine preconditioning against myocardial ischemia/reperfusion injury.
Li HX; Wang TH; Wu LX; Xue FS; Zhang GH; Yan T
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35959640
[TBL] [Abstract][Full Text] [Related]
36. ROS generated during early reperfusion contribute to intermittent hypobaric hypoxia-afforded cardioprotection against postischemia-induced Ca(2+) overload and contractile dysfunction via the JAK2/STAT3 pathway.
Wu L; Tan JL; Wang ZH; Chen YX; Gao L; Liu JL; Shi YH; Endoh M; Yang HT
J Mol Cell Cardiol; 2015 Apr; 81():150-61. PubMed ID: 25731682
[TBL] [Abstract][Full Text] [Related]
37. Dexmedetomidine Preconditioning Protects Cardiomyocytes Against Hypoxia/Reoxygenation-Induced Necroptosis by Inhibiting HMGB1-Mediated Inflammation.
Chen J; Jiang Z; Zhou X; Sun X; Cao J; Liu Y; Wang X
Cardiovasc Drugs Ther; 2019 Feb; 33(1):45-54. PubMed ID: 30675709
[TBL] [Abstract][Full Text] [Related]
38. Dexmedetomidine Protects Cardiomyocytes against Hypoxia/Reoxygenation Injury by Suppressing TLR4-MyD88-NF-
Gao JM; Meng XW; Zhang J; Chen WR; Xia F; Peng K; Ji FH
Biomed Res Int; 2017; 2017():1674613. PubMed ID: 29359143
[TBL] [Abstract][Full Text] [Related]
39. Dexmedetomidine Maintains Its Direct Cardioprotective Effect Against Ischemia/Reperfusion Injury in Hypertensive Hypertrophied Myocardium.
Yoshikawa Y; Hirata N; Kawaguchi R; Tokinaga Y; Yamakage M
Anesth Analg; 2018 Feb; 126(2):443-452. PubMed ID: 28914648
[TBL] [Abstract][Full Text] [Related]
40. Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis.
Wang Z; Yao M; Jiang L; Wang L; Yang Y; Wang Q; Qian X; Zhao Y; Qian J
Biomed Pharmacother; 2022 Oct; 154():113572. PubMed ID: 35988428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
